Clinical Trial Update: Maintenance Therapy With Selinexor and Azacitidine in TP53 Mutant AML/MDS After Transplantation [Phase 1]

View source ↗

Summary

This document provides an update on a Phase 1 trial evaluating maintenance therapy with selinexor and azacitidine in patients with TP53-mutant myelodysplastic s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndrome

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• Selinexor (selinexor)

Snippet

Sponsor: Daihong Liu | Conditions: TP53-mutated MDS and AML, Allogeneic Hematopoietic Stem Cell Transplantation | Phase 1 | Status: ACTIVE_NOT_RECRUITING